- Home
- LC vs CNTA Comparison
LC vs CNTA Comparison
Compare LC & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LC | CNTA |
|---|---|---|
| Founded | 2006 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LC | CNTA |
|---|---|---|
| Price | $19.96 | $26.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | $22.67 | ★ $37.70 |
| AVG Volume (30 Days) | 1.5M | ★ 1.8M |
| Earning Date | 01-27-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 93.62 | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $1,296,102,000.00 | $15,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.10 | N/A |
| P/E Ratio | $22.32 | ★ N/A |
| Revenue Growth | 16.98 | ★ 118.88 |
| 52 Week Low | $7.90 | $9.60 |
| 52 Week High | $20.94 | $30.58 |
Technical Indicators
Market Signals| Indicator | LC | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 64.66 | 45.51 |
| Support Level | $18.98 | $28.43 |
| Resistance Level | $20.94 | $30.02 |
| Average True Range (ATR) | 0.68 | 1.34 |
| MACD | 0.23 | -0.40 |
| Stochastic Oscillator | 78.92 | 18.64 |
Price Performance
Historical ComparisonAbout LC LendingClub Corporation
LendingClub Corp is a company engaged in operating an online lending marketplace platform that connects borrowers and investors for the provision of the loan facility. It offers investors access to an asset class that has generally been closed to many investors and only available on a limited basis to institutional investors. The company through the platform offers loan products such as personal, education and patient finance, small business, and auto to interested investors. It generates a majority of the revenue from the transaction fees received from the platform's role in accepting and decisioning applications on behalf of the bank partners to enable loan originations.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.